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Objective: Stentless mitral xenografts offer potential clinical benefits because they
mimic the normal bileaflet mitral valve. How best to implant them and their
hemodynamic performance and durability, however, remain unknown.
Methods: A stentless porcine mitral xenograft valve (Medtronic physiologic mitral
valve) was implanted in 7 sheep with papillary muscle sewing tubes attached with
transmural left ventricular sutures. Radiopaque markers were inserted on the leaf-
lets, annular cuff, papillary tips, and left ventricle. After 10  5 days, the animals
were studied with biplane videofluoroscopy to determine 3-dimensional marker
coordinates at baseline and during dobutamine infusion. Transesophageal echocar-
diography assessed mitral regurgitation and valvular gradients. Mitral annular area
was calculated from the annular markers. Physiologic mitral valve leaflet and
annular dynamics were compared with 8 native sheep valves.
Results: Average mitral regurgitation grade at baseline was 1.2  1.0 (range, 0-4),
and the mean transvalvular pressure gradients were 3.6 1.3 and 6.2 2.2 mm Hg
during baseline and dobutamine infusion, respectively. Xenograft mitral annular
area contraction throughout the cardiac cycle was reduced (6% 6% vs 13% 4%
for physiologic mitral valve and control valve, respectively; P  .03). Physiologic
mitral valve leaflet geometry during closure differed from the native valve, with the
anterior leaflet being convex to the atrium and with little motion of the posterior
leaflet. Three animals survived more than 3 months; good healing of the annular cuff
and papillary muscle tubes was demonstrated.
Conclusion: This stentless xenograft mitral valve substitute had low gradients at
baseline and during stress conditions early postoperatively, with mild mitral regur-
gitation. Preliminary analysis of healing characteristics appeared favorable at 3
months. Additional studies are needed to determine long-term xenograft mitral
valve performance and resistance to calcification.
Stentless mitral xenografts might offer potential clinical benefits be-cause the durability of all currently available porcine semilunar bio-prostheses in the high-stress mitral position is suboptimal comparedwith that in the aortic position. A xenograft mitral bioprosthesis isnaturally bileaflet, which would better mimic nature’s design for theatrioventricular position; theoretically, this should translate into en-
hanced clinical durability (freedom from structural valve dysfunction). The hemo-
dynamic performance, durability, and technical feasibility of implanting unstented
mitral xenografts, however, still need to be determined. Limited clinical experience
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with unstented mitral prostheses has been reported period-
ically in the literature since the experimental inception of
mitral homografts almost 40 years ago.1-3 Although early
results of homograft mitral valve replacement in patients
were disappointing after structural valve dysfunction,4,5 ad-
vances in surgical techniques6 and improved understanding
of mitral physiology have spurred a renewed clinical inter-
est in stentless mitral valve substitutes.7-9
The theoretic advantages of stentless mitral homografts and
xenografts over traditional stented bioprostheses include better
hemodynamic performance, lower thrombogenicity, resistance
to infection, preservation of valvular-ventricular continuity8
(which helps maintain left ventricular [LV] systolic pump
function10,11), and possibly enhanced structural durability. The
availability of suitable mitral homograft valves is limited,
however, and valve implantation techniques are demanding
and require considerable experience. Although good results
have been obtained in a few centers with mitral unstented
homografts12 and xenografts,13 consistent clinical outcomes
have not been universal.14,15 The heterogeneity of papillary
muscle (PM) anatomy in the human heart16,17 also compli-
cates homograft implantation techniques.
Porcine xenografts offer the advantage of plentiful avail-
ability and more consistent subvalvular anatomy, but their
hemodynamic performance and optimal implantation tech-
nique are not known. We have previously reported on the
feasibility of implanting a stentless porcine mitral xenograft
(Medtronic physiologic mitral valve [PMV]) in a sheep
model and its immediate postoperative hemodynamic per-
formance (acute open-chest preparation).18 In the current
experiment, we placed radiopaque markers on this porcine
mitral xenograft to evaluate valvular dynamics and gradi-
ents and leaflet 3-dimensional (3-D) motion at rest and
during inotropic stimulation 10 days after implantation.
Methods
The PMV stentless porcine xenograft was implanted in 22 adult
sheep on cardiopulmonary bypass (CPB). Seven animals survived
beyond 24 hours and were subsequently evaluated at 6 to 19 days
(mean, 10 5 days) postoperatively under conscious, closed-chest
conditions. Mitral annular and leaflet dynamics were compared
with those of a control group of 8 sheep that underwent marker
implantation only and were subsequently studied after 7 to 10 days
(mean, 7  1 days).
Porcine Mitral Xenograft
Porcine mitral valves were harvested from adult pig hearts and
removed with the anulus, leaflets, chordae, and PMs intact by
Medtronic Heart Valve Division (Minneapolis, Minn). The PMV
design has been modified since our earlier preliminary experi-
ment,18 including UltiFix fixation, a pliable annular sewing cuff of
UltiFix-preserved porcine pericardium, and Dacron velour sewing
tubes attached to each PM head. The valve and subvalvular appa-
ratus were fixed in UltiFix solution, a nonglutaraldehyde process
that forms amide bonds with carbodiimide cross-linking in the
presence of coupling agents. Tissue cross-linking is as good as
glutaraldehyde on the basis of shrinkage temperature and enzy-
matic digestion analysis. It is biocompatible and resists calcifica-
tion, as demonstrated in both the rat subdermal and juvenile sheep
models.19 The anatomy of the porcine mitral valve is different than
that in sheep or human subjects: The orientation of the pig PMs is
approximately 180° to each other, and the areas and heights of the
porcine anterior and posterior leaflets are approximately equal.
PMV size was selected on the basis of animal weight (PMV to
native valve size correlations derived from previous acute, open-
chest experiments), and 8 miniature radiopaque markers were
sewn around the anulus of the xenograft: 1 on each PM head, 4 on
the central portion of the anterior leaflet, and 2 on the central
portion of the posterior leaflet (Figure 1, A).
Surgical Procedure
The techniques for marker20 and porcine xenograft18 implantation
have been described previously. The animals were premedicated
with ketamine (25 mg/kg administered intramuscularly), and an-
esthesia was induced with sodium thiopental (6.8 mg/kg adminis-
tered intravenously) and maintained with inhalational isoflurane
(1%-2.2%). Eight tantalum myocardial markers (inner diameter,
0.8 mm; outer diameter, 1.3 mm; length, 1.5-3.0 mm) were in-
serted beneath the LV epicardial surface along 4 equally spaced
longitudinal meridians, and an additional marker was placed at the
LV apex. Subsequently, the anterior ovine mitral leaflet was ex-
cised, leaving 2 to 3 mm remaining along the anulus. The posterior
mitral leaflet and its chordal attachments were left intact to provide
more tissue for suturing of the xenograft anulus, especially in the
commissural areas. Mitral xenografts were sized on the basis of
animal weight. The size was based on prior short-term experiments
in which the intertrigonal distance and the area of the anterior
leaflet of the native valve were measured to choose the appropriate
size for the prosthesis.18 In the current series we selected the
appropriately sized prosthesis before CPB to allow the markers to
be sewn to the xenograft before implantation. The rinsed xenograft
(3 at 29 mm, 2 at 31 mm, and 2 at 35 mm) was placed within the
LV cavity in an anatomic orientation, and the length of the PM
sewing tubes was assessed. In most cases the Dacron tubes were
shortened to allow the PM tips to be positioned within the ventricle
at a level sufficiently apical to prevent leaflet prolapse (which
depended on the size of the ventricle and the length of the sewing
tubes) and sutured to the LV wall at the appropriate level with the
PMV anterior PM located near the recipient’s native anterolateral
PM and the PMV posterior PM being sutured adjacent to the
recipient’s posteromedial PM, such that they were approximately
180° opposite to each other, rather than the normal 120° to 150°
angle between the sheep’s native PMs.18 Two transmural 1-0
braided polyester horizontal mattress sutures secured each PM
sewing tube, with the sutures tied over a Teflon felt pledget on the
LV epicardial surface. Care was taken to avoid coronary arteries.
By using two 4-0 polypropylene sutures starting at the fibrous
trigones, the PMV xenograft sewing ring was sutured to the native
anulus in running fashion (Figure 1, B). There was size mismatch
for the two 35-mm valves when the native anulus was smaller,
even when large sheep were used (90 kg). This mismatch was
addressed by means of annular plication. The animal was re-
warmed, the atriotomy was closed, the crossclamp was removed,
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and the animal was weaned from bypass. A micromanometer
pressure transducer (PA4.5-X6; Konigsberg Instruments, Inc, Pas-
adena, Calif) was placed in the LV chamber through the apex.
Epicardial echocardiography was used to assess immediate valve
function and transvalvular gradients. After extubation, the animals
recovered in the experimental animal cardiac surgical intensive
care unit. Eight control animals from an earlier experiment had
markers implanted on the left ventricle and the native ovine valve
in the same array as for the xenograft (Figure 1, A).
Experimental Protocol
After 10 5 days’ recovery, the sheep were sedated with propofol
(150-300 mg/h) and diazepam (5-mg intravenous bolus as needed)
and intubated. Intravenous esmolol infusion (20-50 g  kg1 
min1) was used to minimize reflex sympathetic responses. A
Swan-Ganz catheter was placed through the left internal jugular
vein for measurement of cardiac output. Simultaneous biplane
videofluoroscopy, hemodynamic data recordings, and transesoph-
ageal pulse-wave and color Doppler echocardiography were con-
ducted under 2 experimental conditions in the PMV group: (1)
baseline and (2) inotropic stimulation with dobutamine (10 g 
kg1  min1). In the control animals only baseline data were
obtained. The PMV animals were subsequently allowed to recover
and then electively killed at 3 to 4 months after valve implantation.
All animals received humane care in compliance with the “Prin-
ciples of Laboratory Animal Care” formulated by the National
Society for Medical Research and the “Guide for the Care and Use
of Laboratory Animals” prepared by the Institute of Laboratory
Animal Resources, National Research Council, and published by
the National Academy Press, revised 1996. This study was ap-
proved by the Stanford Medical Center Laboratory Research An-
imal Review Committee and conducted according to Stanford
University policy.
Data Acquisition
Images were acquired with the animal in the right lateral decubitus
position with a Philips Optimus 2000 biplane Lateral ARC 2/Poly
DIAGNOST C2 system (Phillips Medical Systems, North America
Company, Pleasanton, Calif) with the image intensifier in the
9-inch fluoroscopic mode. Data from 2 radiographic views were
digitized and merged to yield 3-D coordinates for each of the
radiopaque markers every 16.7 seconds by using custom-designed
software.21 Ascending aortic pressure, LV pressure, and electro-
cardiographic voltage signals were digitized and recorded simul-
taneously during data acquisition.
Data Analysis
Two steady-state beats from each animal in the control and PMV
groups were averaged and defined as control and PMV data,
respectively. During each cardiac cycle, the time of end-systole
was defined as the videofluoroscopic frame containing the point of
peak rate of LV pressure fall (dP/dt), whereas the time of
end-diastole was defined as the videofluoroscopic frame contain-
ing the peak of the electrocardiographic R wave. Instantaneous LV
volume was calculated from the epicardial LV markers with the
use of a space-filling multiple tetrahedral volume method for each
frame (ie, every 16.7 ms).22 Although myocardial volume is in-
cluded in this calculation of LV volume (thereby overestimating
end-diastolic LV volume), this parameter accurately reflects rela-
tive changes in LV chamber size.
Mitral Annular and Leaflet Dynamics
Mitral annular area (MAA) was calculated as the sum of multiple
triangular areas, each from 2 adjacent annular markers and the 3-D
centroid20 of the annular markers (Nos. 1-8; Figure 1, A). MAA
contraction (MAA) was determined as the percentage change
Figure 1. A, Schematic representation of the annular and leaflet marker array used in the study. Annular markers
are shown as circles, and leaflet markers are shown as squares. ACOM, anterior commissure; PCOM, posterior
commissure. B, Intraoperative photograph of the implanted stentless PMV bioprosthetic mitral valve. AML with
attached gold markers is visible through the valve orifice.
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throughout the cardiac cycle from maximum to minimum area. A
plane was fitted to the posterior annular markers (Nos. 3-7; Figure
1, A) by using least-squares estimation to quantify the amount of
annular folding or tilting during the cardiac cycle. Septal (anterior)
annular elevation was defined as the vertical distance of marker 1
(saddle-horn marker; Figure 1, A) from that plane.
Anterior mitral leaflet (AML) and posterior mitral leaflet
(PML) lengths were calculated as the sum of individual segments
defined by the implanted markers on the central portion of each
leaflet. Angular position of the anterior leaflet edge was calculated
throughout the cardiac cycle as the angle (AML) between the
anterior leaflet edge marker (No. 12) and the midseptal (No. 1) and
midlateral (No. 5) anulus. Posterior leaflet edge angular position
(PML) was calculated in a similar fashion. For 3-D reconstruction
of annular and leaflet shape, an internal right-handed Cartesian
coordinate system was defined with the origin located at the
midseptal anulus marker (No. 1), the positive X-axis directed
toward the midlateral anulus (marker No. 5), the positive Y-axis
directed toward the LV apex, and the positive Z-axis directed
toward the posterior commissure. The midseptal anulus was cho-
sen as the origin because it is at the center of the fibrous anulus and
represents an anatomic landmark that is relatively stable in labo-
ratory coordinates.
Statistical Analysis
All data are reported as means  1 SD, unless otherwise stated.
Hemodynamic and marker-derived data from 2 consecutive
steady-state beats were aligned at end-diastole (t  0), and data
from the 2 beats were averaged over all animals in each group. The
data (time aligned at end-diastole) were analyzed from 20 frames
before to 20 frames after end-diastole, thereby allowing evaluation
of the studied variables over the entire cardiac cycle. Data were
compared with the Student t test for paired observations (PMV
baseline vs dobutamine) and independent observations (control vs
PMV).
Results
Surgical Outcome
Seven of the 22 animals that underwent implantation of the
PMV xenograft survived beyond 24 hours. Of the 15 deaths,
6 were caused by early pulmonary failure, 2 were caused by
bleeding, 1 was caused by a stroke, and 1 was caused by
premature self-extubation. Five of the deaths were directly
related to technical aspects of implantation. Three animals
died of leaflet prolapse and severe mitral regurgitation (MR;
technical errors) when the PM sewing tubes were not in-
serted apically enough. The 2 other valve-related deaths
were due to annular dehiscence near the anterior commis-
sure in one animal and posterior PM sewing tube dehiscence
in another, causing severe MR. There was a considerable
learning curve (no survivors in the first 10 attempted im-
plantations, but 7 of 12 survivors subsequently); this was
primarily due to a lower incidence of respiratory failure,
which was linked to shortening the CPB time and using
aprotinin for its putative lung protective and anti-inflamma-
tory effects. The CPB and aortic crossclamp times for the
first 10 animals were 130  23 and 87  15 minutes,
respectively, but fell to 96  13 and 64  6 minutes in the
last 12 animals. Mean aortic crossclamp time for the sur-
viving 7 PMV animals who were cathetherized did not
differ from that of the 8 control animals (64  8 vs 61  3
minutes, P  .4), although their total CPB time was some-
what longer (93  11 vs 82  5 minutes, P  .04). There
was no difference in weight between the 2 groups (76  14
and 76  9 kg for PMV and control groups, respectively;
P  .9).
Hemodynamics
Table 1 summarizes the hemodynamics of control and PMV
animals during baseline conditions. There was no signifi-
cant difference between the groups in heart rate, LV dP/dt,
peak LV pressure, end-systolic and end-diastolic volumes,
or stroke volume. These data indicate comparable loading
and hemodynamic conditions between the 2 groups, thus
allowing direct comparison of valvular performance and
dynamics. Hemodynamic variables before and after dobut-
amine infusion in the PMV animals are shown in Table 2,
and these indicated a markedly enhanced inotropic state.
Cardiac output increased by 61% during dobutamine infu-
sion, which allowed assessment of valvular hemodynamics
and leaflet 3-D motion during high flow conditions.
TABLE 1. Hemodynamics
Control PMV P value
HR (beats/min) 99 8 109 20 .2
dP/dtMAX (mm Hg) 1455 287 1322 397 .5
LVPMAX (mm Hg) 119 13 108 9 .09
EDV (mL) 155 28 176 25 .15
ESV (mL) 119 26 137 15 .14
SV (mL) 36 7 40 12 .5
Data are shown as mean SD. P value by means of t test for independent
observations.
HR, Heart rate; dP/dtMAX, maximum positive rate of change of LV pressure;
LVPMAX, maximum systolic LV pressure; EDV, LV end-diastolic volume; ESV,
LV end-systolic volume; SV, stroke volume.
TABLE 2. PMV hemodynamics with dobutamine
Baseline Dobutamine P value
HR (beats/min) 109 20 138 14 .006
dP/dtmax (mm Hg) 1322 397 2452 766 .002
LVPmax (mm Hg) 108 9 134 17 .006
EDV (mL) 176 25 174 25 .12
ESV (mL) 137 15 128 15 .005
CO (L/min) 4.5 1.3 7.0 1.4 .0001
Data are shown as mean  SD. P value by means of t test for paired
observations.
HR, Heart rate; dP/dtMAX, maximum positive rate of change of LV pressure;
LVPMAX, maximum systolic LV pressure; EDV, LV end-diastolic volume; ESV,
LV end-systolic volume; CO, cardiac output.
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Echocardiographic Evaluation
The Doppler mean and peak valvular gradients across the
PMV immediately after weaning from CPB (open-chest
epicardial imaging) were 2.4  1.2 and 4.4  2.1 mm Hg,
respectively. At an average of 10 days postoperatively
(closed-chest imaging), the transesophageal echocardio-
graphic Doppler mean and peak gradients were 3.6  1.3
and 6.6  0.9 mm Hg during baseline conditions and
increased to 6.2  2.2 mm Hg (P  .01) and 9.8  5.3 mm
Hg (P  .14) during dobutamine infusion. In 1 animal a
reliable gradient could not be obtained during dobutamine
infusion because of echocardiographic technical difficulties.
Analysis of leaflet motion revealed good leaflet opening and
mobility of the anterior PMV leaflet but very limited motion
of the posterior leaflet. Color Doppler imaging showed MR
to be absent in 1 animal, trace in 1 animal, mild in 3
animals, moderate in 1 animal, and moderate to severe in
another animal, yielding an average MR grade of 1.2  1.0.
The moderate MR in 1 animal was a result of placing
papillary sewing tubes apically too far apart, resulting in
leaflet restriction, whereas the animal with moderate-to-
severe MR had only trace insufficiency immediately post-
operatively but subsequently had a large perivalvular leak.
Mitral Annular Dynamics
MAA and elevation of the septal (anterior) anulus above the
lateral annular plane throughout the cardiac cycle for con-
trol and PMV animals are shown in Figure 2. After implan-
tation, the motion of the stentless PMV mitral xenograft
anulus was reduced, with only a 6% MAA change through-
out the cardiac cycle (Table 3). This was most likely related
to the significant reduction of maximum MAA by 35% (P
Figure 2. Group mean MAAs (in square centimeters, top panel) and septal anulus elevation (in centimeters, bottom
panel) throughout the cardiac cycle for control animals (filled squares) and PMV animals (open squares). Data are
centered at end-diastole (t  0), with a 650-ms time window shown. Error bars equal 1 SEM.
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.002), resulting from suturing the PMV around the mitral
anulus, similar to an annuloplasty ring effect. However,
folding of the septal anulus, defined as the change in dis-
tance of the midseptal marker to the posterior annular plane
during systole, was similar in the 2 groups, suggesting that
annular flexibility or folding was maintained with the PMV
valve. The 3-D geometric relationship between the mitral
anulus and the PMs in the control and the PMV study
animals are shown in Figure 3. Although annular shape was
similar, the PMV PM sewing tubes were inserted closer to
the septum because of the natural 180° orientation of the
PMV (porcine) PMs compared with the angle between the
native ovine PM positions.
Mitral Leaflet 3-D Dynamic Motion
Angular excursion of the AMLs and PMLs throughout the
entire cardiac cycle in the control and the PMV animals are
shown in Figure 4 and Table 3. The anterior PMV leaflet
remained very mobile, with total excursion throughout the
cardiac cycle similar to that observed in the control animals.
The posterior PMV leaflet, however, was almost completely
frozen, with an angular excursion of only 10° from maxi-
mum to minimum during the cardiac cycle. Figure 5 shows
a 2-D reconstruction of leaflet shape during valve closure in
both groups. The posterior leaflet of the xenograft had very
limited mobility, and the anterior leaflet had a convex shape
toward the atrium throughout closure compared with the
more concave shape of the anterior leaflet in the control
sheep. Some billowing of the basal portion of the anterior
PMV leaflet was observed, most likely caused by redun-
dancy of PMV leaflet tissue. The distance between the
anterior leaflet edge marker and the annular plane (least-
squares fit of all 8 annular markers) at end-systole did not
differ between the control and PMV animals (0.75  0.19
vs 1.12  0.59 cm for control and PMV, respectively; P 
.14). The distance between the posterior PMV leaflet edge
marker and the anulus, however, was longer (displaced
apically) at end-systole relative to that of the control ani-
mals (1.69  0.61 vs 0.75  0.12 cm, respectively; P 
.002) as a result of limited leaflet mobility, malpositioning,
or both of the PM sewing tube.
Follow-up
Four of the 5 animals survived more than 3 months. One
animal died at 3 weeks postoperatively as a result of right
heart failure. Of the four 3-month survivors, one animal
died of a cerebral embolus after 3 months, and one had
endocarditis. Gross examination of these 4 hearts revealed
good healing and limited pannus formation around the PM
sewing tube insertion sites, with firm fixation to the LV
wall. The anulus was well endothelialized (Figure 6), and
there was normal-appearing pliability of the mitral leaflets
(except in the animal with endocarditis, which had vegeta-
tions and calcification of the valve).
Discussion
Stentless mitral bioprostheses have spurred renewed clinical
interest12,23,24 because the durability and performance of
stented bioprostheses are suboptimal in the mitral posi-
tion.25,26 Compared with mitral homografts, porcine mitral
xenografts offer the advantage of more consistent subval-
vular anatomy and widespread availability. Although they
have been introduced into clinical practice,13,27 their clinical
efficacy is uncertain. In this experiment the Medtronic PMV
had reasonable valvular competence, low transvalvular
pressure gradients at rest, and acceptable transvalvular gra-
dients during inotropic stimulation 10 days after implanta-
tion. There was little dynamic area change of the PMV
mitral anulus, and posterior leaflet motion was limited;
mitral annular folding and anterior leaflet excursion were
comparable with that seen in the control animals’ native
ovine valves. This study extended our preliminary, acute
nonsurvival evaluation of an earlier version of this biopros-
thesis18; analysis of leaflet motion, annular folding, and PM
tip position 10 days postoperatively was included in the
current experiment.
Surgical Technique
Technically, satisfactory implantation of mitral homograft
and xenograft valves presents a new surgical challenge, and
considerable experience is required to achieve good re-
sults.17 In our experiment most of the deaths early on
resulted from pulmonary failure. Sheep lungs do not tolerate
prolonged periods of CPB; pulmonary deaths were rare after
we shortened the CPB times and started using aprotinin. On
the other hand, 5 deaths were directly related to technical
errors, mostly related to not inserting the PM sewing tubes
TABLE 3. Mitral annular and leaflet dynamics
Control PMV P value
MAAMAX (cm
2) 9.06 1.59 5.89 0.25 .0002
MAAMIN (cm
2) 7.90 1.51 5.54 0.56 .01
MAA (%) 13.0 4.0 6.0 6.3 .001
MAFLEX (cm) 0.14 0.08 0.21 0.10 .1
LAML (cm) 2.21 0.34 2.75 0.28 .008
LPML (cm) 1.28 0.14 2.16 0.37 .0003
AML (°) 48 8 41 19 .3
PML (°) 34 12 10 2 .0001
Data are shown as mean SD. P value by means of t test for independent
observations.
MAAMAX, Maximum mitral annular area; MAAMIN, minimum mitral annular
area; MAA, change in mitral annular area from maximum to minimum;
MAFLEX, change in the orthogonal distance from the mid septalanulus to
the posterior annular plane during systole; LAML, anterior mitral leaflet
length; LPML, posterior mitral leaflet length; AML, anterior leaflet excur-
sion angle from maximum to minimum; PML, posterior mitral leaflet
excursion angle from maximum to minimum.
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apically enough. Because the porcine mitral valve has leaf-
lets of almost equal height and longer chordae than the
ovine valve, the PM heads, particularly the posterior PM
head, must be implanted apically distant relative to the
native ovine PM tips to avoid PMV leaflet prolapse. Be-
cause the ovine ventricle is conical in shape and thick
walled, proper implantation of the PM sewing tubes is
difficult because of limited visibility deep in the left ventri-
cle. Furthermore, because of the 180° positioning of the
porcine PM heads relative to the long axis of the ventricle,
the PM sewing tubes of the PMV cannot be simply im-
planted on the recipient’s native PM tips; in this preparation
they ended up being inserted closer to the septal anulus
(Figure 3) to avoid twisting of the subvalvular apparatus.
Size mismatch between the native and xenograft mitral
anulus, on the other hand, proved to be less problematic and
could be corrected by means of annular plication without
obvious compromise of valve function. This resulted, how-
ever, in a substantial cinching effect on the mitral anulus,
which dampened its 3-D motion, similar to what is seen
after mitral ring annuloplasty in experimental animals.28
Although there was a considerable learning curve for us, we
found that with experience, the PMV valve can be im-
planted in a predictable and reproducible fashion with clin-
ically acceptable CPB and aortic crossclamp times.
Previous experimental studies with stentless ovine allo-
grafts in growing sheep revealed that early valve failure was
related to chordal rupture or technical error in PM implan-
tation.29 In patients with an implanted porcine stentless
mitral xenograft, the high rate of valve failure and recurrent
mitral insufficiency were due to valve tissue tears parallel to
the mitral anulus, particularly on the posterior aspect of the
anulus and near the commissures.30 These findings were
often accompanied by chordal rupture, suggesting excessive
tension on the chordal apparatus, possibly related to the
technical aspect of PM implantation. Chordal tears and PM
disruption caused by improper PM implantation have also
been reported in human mitral allografts,14,15 which could
also occur with PMV implantation. We did not observe any
ruptured chordae, but 4 deaths were directly related to
technical errors in PM implantation.
Valvular 3-D Dynamics and Leaflet Motion
As reported in prior clinical12,23,24 and experimental18,29,31
studies of stentless mitral valves, the baseline mean and
peak gradients across the PMV were low. There is a paucity
Figure 3. Group mean data for the 3-D reconstruction of the mitral anulus (squares) and PM tips (triangles) in
control (filled symbols) and PMV (open symbols) animals. Drop lines in all 3 planes (PMs only) are shown for
clarity. Midseptal (1) and midlateral (5) annular markers are labeled for orientation. ACOM, Anterior commissure;
PCOM, posterior commissure; APM, anterior PM; PPM, posterior PM.
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of data on the hemodynamic performance of stentless mitral
bioprostheses under high flow conditions; this experiment
revealed acceptable mean gradients across the PMV xeno-
graft in the face of a 67% increase in cardiac output. For
perspective32-35 (even though direct comparisons between
human subjects and animals are difficult), the mean trans-
valvular gradient in the PMV animals during inotropic
stimulation and high flow conditions was only 1 mm Hg
higher than the average gradient of a quadrileaflet stentless
mitral bioprosthesis in human subjects.36
Although no clinical data exist at the present time, it is
postulated that the superior hemodynamic performance of
stentless mitral bioprostheses might, in large part, be related
to maintained normal annular motion. Surprisingly, dy-
namic MAA change was damped after PMV implantation in
the current study, which was different than that observed in
our earlier acute, open-chest experiment.18 This discordance
might be due to the previous animals being relatively hy-
perdynamic and receiving inotropic drugs immediately
postoperatively because of the differences in the experimen-
tal conditions (open-chest and anesthetized vs closed-chest
and sedated conditions) or perhaps because of a greater
reduction of MAA and more of an annular purse-string
effect in the current PMV series. Similar degrees of MAA
reduction (approximately 30%-35%) after flexible ring an-
nuloplasty have also been shown to abolish mitral annular
dynamics in sheep.28 Folding of the septal anulus in the
PMV xenograft was similar to that in the native ovine
anulus; preservation of normal annular folding might be
important for avoiding LV outflow tract obstruction after
Figure 4. Group mean data for angular displacement of anterior (top panel) and posterior (bottom panel) mitral
leaflet edge angle throughout the cardiac cycle for native mitral leaflets (filled symbols) and PMV leaflets (open
symbols). Data are centered at end-diastole (t  0), with a 650-ms time window displayed. Error bars indicate 1
SEM. Note the cyclic motion of AML but essentially fixed value of PML in the PMV animals.
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annular reduction,37 particularly with the relatively large
amount of tissue in the anterior leaflet of the PMV biopros-
thesis.
This porcine xenograft functioned effectively as a mono-
leaflet valve in vivo, with a frozen posterior leaflet acting as
a buttress against which the AML closed. The PMV anterior
leaflet was concave to the left atrium during closure, with
some relative billowing of the basal portion of the leaflet,
which was different from the closing motion of the native
ovine leaflet. Whether this altered shape reflects abnormal
chordal forces, which could in turn affect leaflet durability
and function, is unclear; however, displacement of the PMV
anterior leaflet edge away from the annular plane did not
differ from that of control hearts, indicating appropriate
restoration of the valvular-subvalvular geometric relation-
ship. Whether limited posterior leaflet motion is related to
reduction of annular size, change in the annular-papillary
distance, or both is speculative, but frozen posterior leaflet
motion has been observed in ovine hearts after annular
reduction with either a flexible or a semirigid annuloplasty
ring38 and also seen commonly in patients after a mitral ring
annuloplasty. Perhaps both annular dynamics and posterior
leaflet motion might be less abnormal if these valves had
been oversized, as is done with mitral homografts clinical-
ly.12,15
Although 3 months’ follow-up is short, and there were
only 4 animals, the preliminary pathologic findings were
encouraging. Excluding the animal that had endocarditis,
Figure 5. Two-dimensional reconstruction of mitral leaflet shape during valve closure (from 34 ms before
end-diastole to 67 ms after end-diastole) in the native ovine valve (top panel) and the porcine mitral xenograft
(bottom panel). Each reconstruction represents mean data from 5 animals at each time point.
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the PMV anulus was completely endothelialized and well
incorporated into the native mitral anulus. The leaflets were
pliable, with only minimal calcification, and the PM sewing
tubes were covered with fibrous tissue and firmly attached
to the LV wall.
Limitations
Leaflet dynamics of the porcine xenograft were compared
with those of the native ovine valve, and the observed
differences might not only be related to technical aspects of
implantation but also to possible interspecies differences in
porcine and ovine mitral valve closing mechanics in vivo.
Radiopaque marker studies require suturing of small mark-
ers on leaflets, which could potentially affect normal leaflet
motion, but both groups of animals had the same kind of
leaflet markers placed in identical arrays. Therefore, any
effects of the composite mass of the markers should be the
same. Furthermore, it is unlikely that the markers interfered
with mitral leaflet motion because they are very small
(aggregate mass, 20  6 mg). Even when we grossly
overloaded the anterior leaflet with a very large number of
excessively heavy markers (total mass, 184 mg) in another
study, the peak anterior leaflet opening velocity determined
by means of epicardial PW Doppler echocardiography was
0.47 0.05 m/s compared with 0.45 0.06 m/s for leaflets
without any markers attached. We placed markers only on
the central portion of each leaflet, and therefore no data on
leaflet shape and dynamics in the commissural parts of the
leaflets are available. Lack of preoperative sizing of the
xenograft and having available a complete set of all sizes of
PMV bioprostheses is another possible limitation; in certain
cases we were forced to implant a valve that obviously was
too long or too large for a particular sheep’s ventricle. More
refined PMV sizing methods (incorporating both mitral
annular size and the length of the LV chamber) and avail-
ability of more sizes will provide better surgical results.
We appreciate the technical assistance provided by Mary K.
Zasio, BA, Carol W. Mead, BA, and Maggie Brophy, AS.
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Discussion
Vaughn Starnes (Los Angeles, Calif). This is yet another in a
continuing series of the mitral valve studies ongoing at Stanford,
and we owe a great deal of gratitude to the group.
This is a very complex model, and I admire your surgical
tenacity with the first 10 preparations dying. I think we can
attribute that to the effects of putting a sheep on CPB and the lung
damage that it will do, but I think we have to focus also on the 5
deaths that seem to be the result of technical problems. All the
PMV animals were studied at 10 days, and I would like to focus on
3 points of the study: valve gradient, valve function, and valve
motion.
I think points about durability can not be surmised from this
study, although we did note there was some early calcification in
some of these valves, as you pointed out in your article. As we
look at valve gradient, we see minimal gradient, an average of
about 3 mm during the control state, 6 peak gradients, and again on
dobutamine infusion, it only rose to about twice that, or 6 mm.
Now we look at valvular function, and this is going to lead to my
first question: Of the valves studied—these were 7 valves—we
have had 1 valve with no leak, 1 valve with 1, 3 valves with 2,
1 valve with 3, and 1 valve with 4, and you mean those to a
score of 1.2, and you said that on the basis of these data, you
believed you had only mild regurgitation as a group. Could you
comment on that? It would seem to me that if you average those
out, we would probably rate most of those valves in the mild-to-
moderate regurgitation group.
Dr Timek. The data in the article were on the first 5 valves, 1
with no regurgitation, 1 with trace regurgitation, and 3 with mild
regurgitation. Of the 2 subsequent animals that were added, there
was one with moderate and one with moderate-to-severe regurgi-
tation. According to that scale, it was 1.2.
Dr Starnes. Another question I have, obviously, in doing this
operation is that we had a lot of technical difficulties in the
beginning, and then we ended up with 7 survivors. Could you tell
us whether you learned during this preparation how to determine
the length of the chordal attachments. It seemed to be the most
difficult part of this operation.
Dr Timek. Thank you. That is a very insightful point. Indeed,
that is the most difficult part of this operation, to decide how deep
the papillary tips must be placed. Initially, we began by placing
them as far apically as possible, and in sheep with normal ventri-
cles, that did not seem to be a wrong thing to do. We also tried to
measure them with a custom-designed tape, and that has also
helped us. One of the problems that we have had is that because of
the valve availability, we cannot always match the size of the valve
with the size of the sheep, and therefore it is somewhat subjective
where the papillary tip is placed. We are currently still working on
how to refine that technique because that has really been the major
portion of our technical failures, where the papillary muscle tips
are placed.
Dr Starnes. With the sheep’s heart being more conical than
elliptical, would you anticipate the implantation in the human
subject to be easier?
Dr Timek. We would like to think so; however, at this point,
we can not comment on that, although it would seem reasonable
that in a dilated ventricle, where you could excise the entire valve,
you probably would have good exposure, and perhaps it would be
easier to implant these valves. However, that is all wishful think-
ing.
Dr Starnes. I would like to turn now to the leaflet motion.
Again, because of the excellent technical capabilities of the labo-
ratory, you were able to follow the physiologic motion of the
anterior and posterior leaflets. The results revealed a mobile ante-
rior leaflet and a fixed posterior leaflet. This brings me to my
second question. Do you believe the immobile posterior leaflet was
due to chordal positioning, or do you believe it is due to the
retained posterior leaflet and chordae apparatus that I noticed you
left in these animals? In other words, you did not excise the
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posterior leaflet. Could that have been the effect of your immobile
leaflet posteriorly?
Dr Timek. That is a very good question. The reason for leaving
the posterior leaflet in is to provide extra tissue to sew the PMV
valve because the ovine mitral anulus is rather fine. In terms of
freezing the posterior leaflet, we have seen that with any type of
annular reducing procedure, such as a ring annuloplasty, either a
flexible or rigid anulus, when we reduce the annular size, we also
freeze the PML. In this experiment you see that for weight-
matched animals, the anulus is reduced by about 30% in the PMV
valves, and that is approximately what we see with annuloplasty
rings. We believe that one reason why the posterior leaflet is frozen
is because of the annular reduction. Of course, the second possible
and likely reason is the placement of the papillary muscle tips.
How to differentiate those is difficult to say, but we suspect that
both contribute.
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